Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.
Brief Summary: This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary study hypothesis is that at Week 26, the mean reduction from baseline in hemoglobin A1c (HbA1c) for ertugliflozin is greater than that for placebo.


Options:
A: Arm Label: Ertuglifozin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ertugliflozin 5 mg, Drug: Placebo to Ertugliflozin, Other: Glimepiride, Drug: Placebo to Glimepiride, Biological: Basal Insulin, Drug: Metformin | Arm Label: Ertugliflozin 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Ertugliflozin 15 mg, Other: Glimepiride, Drug: Placebo to Glimepiride, Biological: Basal Insulin, Drug: Metformin | Arm Label: Placebo/Glimepiride; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Ertugliflozin, Other: Glimepiride, Biological: Basal Insulin, Drug: Metformin | Intervention Type: DRUG; Name: Ertugliflozin 5 mg; Assigned to Arm(s): Ertuglifozin 5 mg | Intervention Type: DRUG; Name: Ertugliflozin 15 mg; Assigned to Arm(s): Ertugliflozin 15 mg | Intervention Type: DRUG; Name: Placebo to Ertugliflozin; Assigned to Arm(s): Ertuglifozin 5 mg, Placebo/Glimepiride | Intervention Type: OTHER; Name: Glimepiride; Assigned to Arm(s): Ertugliflozin 15 mg, Ertuglifozin 5 mg, Placebo/Glimepiride | Intervention Type: DRUG; Name: Placebo to Glimepiride; Assigned to Arm(s): Ertugliflozin 15 mg, Ertuglifozin 5 mg | Intervention Type: BIOLOGICAL; Name: Basal Insulin; Assigned to Arm(s): Ertugliflozin 15 mg, Ertuglifozin 5 mg, Placebo/Glimepiride | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Ertugliflozin 15 mg, Ertuglifozin 5 mg, Placebo/Glimepiride
B: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Linagliptin Placebo | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Linagliptin Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
C: Arm Label: Sitagliptin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin (MK0431) | Arm Label: Glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glipizide | Intervention Type: DRUG; Name: sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: glipizide; Assigned to Arm(s): Glipizide
D: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride

Answer: A